Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 4/20 | 0.34 |
| ▸ | F10 | P00742 | 4/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27276624 | 0.99 | RHEB (0.35) | RHEBF10F2TRPA1 | |
| SCHEMBL27276124 | 0.85 | F10 (0.48) | F10F2 | |
| SCHEMBL30967772 | 0.85 | F10 (0.48) | F10F2 | |
| SCHEMBL27276764 | 0.84 | BRD4 (0.31) | — | |
| SCHEMBL30840753 | 0.84 | BRD4 (0.31) | — | |
| SCHEMBL30840760 | 0.84 | BRD4 (0.31) | — | |
| Iodide SCHEMBL30805025 | 0.84 | RHEB (0.30) | RHEBTRPA1 | |
| SCHEMBL27276611 | 0.83 | RHEB (0.31) | RHEBTRPA1 | |
| Iodide SCHEMBL30841178 | 0.82 | TRPA1 (0.34) | TRPA1 | |
| Iodide SCHEMBL30840750 | 0.82 | TRPA1 (0.34) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| EP-4583972-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Sionna Therapeutics Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-06-19 | — | — | US | disclosed |
| WO-2024054840-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | RHEB 1600/4885F10 935/4885F2 2724/4885 |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | RHEB 1600/4885F10 935/4885F2 2724/4885 |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | RHEB 1622/4885F10 792/4885F2 2655/4885 |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | RHEB 1111/4885F10 3549/4885F2 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.